Fisher & Paykel Healthcare dodges worst of US tariff risk: Jarden

Fisher & Paykel Healthcare dodges worst of US tariff risk: Jarden
About 43% of Fisher & Paykel Healthcare’s revenue comes from the US. (Image: Supplied)
John Anthony
Jarden has raised its rating and target share price for Fisher & Paykel Healthcare by 10%, as Thursday’s US tariff announcements proved less damaging than expected.Following US President Donald Trump’s unveiling of “Liberation Day” tariffs, shares in Fisher & Paykel Healthcare (FPH), a company with significant export exposure to the US, traded as low as $32.60 in the wake of the announcement on Thursday. They were currently at $34.80.In a research note released late Thursday evening, Jarden analysts Adrian Allbon...

More Economy

Hawkesby stresses need for central bank independence
Economy

Hawkesby stresses need for central bank independence

Ten years ago a US president would not have openly insulted a Fed chair. 

Rebecca Howard 29 Oct 2025
Restaurant Brands NZ's indy directors say low offer still tasty
Retail

Restaurant Brands NZ's indy directors say low offer still tasty

Below-valuation offer for Restaurant Brands NZ recommended by independent directors.

Staff reporters 28 Oct 2025